The ACSR is committed to supporting the next generation of HIV researchers by offering a grant award program for early-stage investigators interested in conducting HIV-related research, especially for malignancies. The goal is to encourage novel and rigorous scientific research projects that utilize biospecimens and data in the ACSR inventory via a small grant funding mechanism and contribute toward greater understanding of HIV disease, biology, improved treatment, and discovery of a cure.  See below to learn more about our Young Investigator Pilot Award opportunities as well as our past and current awardees. Click here to register for email updates about this and other HIV funding opportunities.

ACSR Funding Opportunities

 

MEET OUR YOUNG INVESTIGATOR PILOT AWARD AWARDEES!

 

  • ACSR YOUNG INVESTIGATOR PILOT AWARD: FALL LOI CYCLE IS CLOSED!  Please contact us for more information on upcoming cycles.

Other Funding Opportunities

Funding opportunities from non-ACSR sources.

  • AIDS Malignancy Consortium: Closed to applications.
  • National Institutes of Health (NIH) Funding Opportunity Announcements 
    • The HU CFAR Monkeypox Rapid Response Grant Program seeks to support and catalyze rapid response research at Harvard University and its affiliated institutions focused on the emerging monkeypox
      epidemic, in the context of HIV. The Monkeypox Rapid Response RFP has a rolling deadline, and applications will be administratively reviewed as they are received. See the fill announcement here: https://files.constantcontact.com/c70eae87001/45ffa64b-67a7-4351-9d76-7ce612f84593.pdf?rdr=true
    • Early Investigator Advancement Program (EIAP)   With the support of the NCI Equity Council, the National Cancer Institute (NCI) launched the Early Investigator Advancement Program (EIAP) in 2021 to facilitate the advancement of scientists from diverse backgrounds to become independent investigators. The Early Investigator Advancement Program has extended its deadline — the program will now accept applications until *December 1, 2022.*
    • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) (PAR-21-246) aims to support locally relevant research in critical areas of HIV-associated noncommunicable diseases at LMIC institutions, to enhance research capacity and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH). This includes exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Application Due Date December 8, 2022
    • Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)  Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.  Open Date (Earliest Submission Date) November 15, 2022. Application Due Date December 15, 2022.
    • Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae. Open Date (Earliest Submission Date) November 15, 2022. Application Due Date December 15, 2022.
    • Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits applications from institutions/organizations to participate as the Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network. The 'CASCADE' Network will conduct pragmatic clinical trials evaluating effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. ‘CASCADE’ clinical trials will be conducted in intended-use environments in resource-constrained settings in low and middle-income countries and in regions with health disparities in the United States, and will have four major scientific focus areas: increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments for cervical cancer prevention in women with HIV. Evidence from these trials is expected to inform clinical practice guidelines and improve implementation of cervical cancer prevention and control programs. Letter of Intent Due Date: November 28, 2022  Application Date: December 28, 2022